Sobi® (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage biotechnology company focused on developing a next-generation treatment for gout. The acquisition strengthens Sobi’s gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in two fully recruited global Phase 3 clinical studies for the potential management of progressive and tophaceous gout and expected to read out in 2026. Pozdeutinurad complements Sobi’s pipeline by adding a potentially best-in-class URAT1 inhibitor for patients sub-optimally treated with first-line therapies.
Read the full article: Sobi to Acquire Arthrosi Therapeutics //
Source: https://www.prnewswire.com/news-releases/sobi-to-acquire-arthrosi-therapeutics-strengthening-pipeline-for-the-potential-treatment-of-gout-302641648.html